A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma
暂无分享,去创建一个
H. Burris | W. Novotny | A. Ashkenazi | M. Fanale | L. Yee | J. Ing | K. Dimick | S. Calvert | C. Robins